Abstract
Breast cancer is the most common cancer in women, with roughly half a million deaths per year worldwide. Among various approaches for breast cancer treatment, chemotherapy is predominantly used for patients at stages II-IV, and monoclonal antibody (mAb) therapy is used for patients with human epidermal growth factor receptor 2 (HER2) overexpression. Integrating the tumor specificity provided by unique mAbs and cytotoxicity of small molecule drugs, antibody-drug conjugates (ADCs) are a series of smart chemotherapeutics that have recently shown great promise in treating a number of cancer types. ADCs are designed to selectively attack and kill cancer cells with minimal toxicity to normal tissues. Ado-Trastuzumab emtansine (T-DM1) was the first and only ADC approved by the US Food and Drug Administration for HER2-positive breast cancer. Following the success of T-DM1, many novel ADCs have been developed, and their anticancer efficacies are currently undergoing preclinical or clinical investigation. The development of ADCs is a rapidly progressing field, and this review aims to summarize the most recent advances in ADCs targeting breast cancer over the past five years (2011-2016). The review highlights compositions and mechanisms of action of these newly developed ADCs and discusses current challenges and future directions of developing new ADCs for improved treatment of breast cancer.
Keywords: Antibody-drug conjugates, breast cancer, drug-antibody ratios, monoclonal antibody, targeted therapy, antigen.
Current Medicinal Chemistry
Title:Recent Advances in Antibody-Drug Conjugates for Breast Cancer Treatment
Volume: 24 Issue: 23
Author(s): Shanshan Deng, Zongtao Lin and Wei Li *
Affiliation:
- 881 Madison Avenue, Room 561, Memphis, TN 38163,United States
Keywords: Antibody-drug conjugates, breast cancer, drug-antibody ratios, monoclonal antibody, targeted therapy, antigen.
Abstract: Breast cancer is the most common cancer in women, with roughly half a million deaths per year worldwide. Among various approaches for breast cancer treatment, chemotherapy is predominantly used for patients at stages II-IV, and monoclonal antibody (mAb) therapy is used for patients with human epidermal growth factor receptor 2 (HER2) overexpression. Integrating the tumor specificity provided by unique mAbs and cytotoxicity of small molecule drugs, antibody-drug conjugates (ADCs) are a series of smart chemotherapeutics that have recently shown great promise in treating a number of cancer types. ADCs are designed to selectively attack and kill cancer cells with minimal toxicity to normal tissues. Ado-Trastuzumab emtansine (T-DM1) was the first and only ADC approved by the US Food and Drug Administration for HER2-positive breast cancer. Following the success of T-DM1, many novel ADCs have been developed, and their anticancer efficacies are currently undergoing preclinical or clinical investigation. The development of ADCs is a rapidly progressing field, and this review aims to summarize the most recent advances in ADCs targeting breast cancer over the past five years (2011-2016). The review highlights compositions and mechanisms of action of these newly developed ADCs and discusses current challenges and future directions of developing new ADCs for improved treatment of breast cancer.
Export Options
About this article
Cite this article as:
Deng Shanshan, Lin Zongtao and Li Wei *, Recent Advances in Antibody-Drug Conjugates for Breast Cancer Treatment, Current Medicinal Chemistry 2017; 24 (23) . https://dx.doi.org/10.2174/0929867324666170530092350
DOI https://dx.doi.org/10.2174/0929867324666170530092350 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Identification of Potential MEK1 Inhibitors by Pharmacophore-based Virtual Screening and MD Simulations
Letters in Drug Design & Discovery Targeting the Akt Kinase to Modulate Survival, Invasiveness and Drug Resistance of Cancer Cells
Current Medicinal Chemistry Glucuronides in Anti-Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents A Perspective on 10-Years HTS Experience at the Walter and Eliza Hall Institute of Medical Research – Eighteen Million Assays and Counting
Combinatorial Chemistry & High Throughput Screening Use of ‘Omic’ Approaches in Unraveling Mechanisms of Gene-Environment Interactions
Current Genomics CYP24A1 as a Potential Target for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Molecular Profiling - An Essential Technology Enabling Personalized Medicine in Breast Cancer
Current Drug Targets Imaging of Hypoxia Using PET and MRI
Current Pharmaceutical Biotechnology Technology Whitespaces India Should Focus: A Comparative Anti-Cancer Patent Rational Analysis of Indian and International Public Funded Universities
Recent Patents on Anti-Cancer Drug Discovery EZN-2208 (PEG-SN38), A 40 kDa Polyethylene Glycol (PEG) Conjugate, As an Anticancer Agent: Review of Preclinical and Clinical Data
Current Bioactive Compounds Radiotherapy for Non-Melanoma Skin Cancer
Current Cancer Therapy Reviews The Urokinase Plasminogen Activator System: Role in Malignancy
Current Pharmaceutical Design Lipid-based Nanoplatforms in Cancer Therapy: Recent Advances and Applications
Current Cancer Drug Targets Epigenetic Modulation: A Promising Avenue to Advance Hematopoietic Stem Cell-Based Therapy for Severe Autoimmune Disorders
Epigenetic Diagnosis & Therapy (Discontinued) Strategies for the Design of Non-peptide CCK2 Receptor Agonist and Antagonist Ligands
Current Topics in Medicinal Chemistry Pidotimod and Immunological Activation in Individuals Infected with HIV
Current HIV Research Modulation of Sensitivity to Antitumor Agents by Targeting the MAPK Survival Pathway
Current Pharmaceutical Design Mammary Development and Breast Cancer: The Role of Stem Cells
Current Molecular Medicine Targeting the EGFR-family for Therapy: Biological Challenges and Clinical Perspective
Current Pharmaceutical Design Clinical Trials with Intracerebral Convection-Enhanced Delivery of Targeted Toxins in Malignant Glioma
Reviews on Recent Clinical Trials